Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer.
The names of the study drugs involved in this study are Niraparib and Osimertinib.
Phase 1 Study of Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer
- ClinicalTrials.gov Identifier: NCT03891615
- Protocol Number: 18-613
- Principal Investigator: Daniel Costa
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required